TOday’s Movers: Penumbra (PEN) Stock Rating Reconfirmed by Analysts at BMO Capital; $140 Target Price Indicates -8.05 % Potential

May 9, 2018 - By reb123z

Penumbra, Inc. (NYSE:PEN) Logo

Penumbra (PEN) Rating Reaffirmed

In an analyst report revealed to clients and investors this morning, BMO Capital restate their “Market Perform” rating on Penumbra (PEN) shares. The target indicates a possible downside of -8.05 % from company’s current stock price.

Penumbra, Inc. (NYSE:PEN) Ratings Coverage

Among 6 analysts covering Penumbra Inc (PEN), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Penumbra Inc has $145 highest and $110.0 lowest target. $137’s average target is -10.02% below currents $152.25 stock price. Penumbra Inc had 12 analyst reports since December 12, 2017 according to SRatingsIntel. BMO Capital Markets downgraded Penumbra, Inc. (NYSE:PEN) on Tuesday, December 12 to “Hold” rating. Canaccord Genuity maintained Penumbra, Inc. (NYSE:PEN) on Friday, January 5 with “Buy” rating. The rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, February 28. The rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, May 9. The rating was maintained by Wells Fargo on Wednesday, February 28 with “Outperform”. The firm earned “Neutral” rating on Tuesday, January 2 by JP Morgan. The stock has “Buy” rating by Canaccord Genuity on Wednesday, April 4. The firm has “Buy” rating given on Thursday, January 18 by Canaccord Genuity. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, February 28 report.

The stock increased 12.03% or $16.35 during the last trading session, reaching $152.25. About 1.15 million shares traded or 347.50% up from the average. Penumbra, Inc. (PEN) has risen 41.68% since May 10, 2017 and is uptrending. It has outperformed by 30.13% the S&P500.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company has market cap of $5.22 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It has a 1171.15 P/E ratio. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

More important recent Penumbra, Inc. (NYSE:PEN) news were published by: Prnewswire.com which released: “Penumbra, Inc. Reports First Quarter 2018 Financial Results” on May 08, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway”, Globenewswire.com published: “Report: Developing Opportunities within Modine Manufacturing, FleetCor Technologies, athenahealth, Penumbra …” on April 27, 2018. More interesting news about Penumbra, Inc. (NYSE:PEN) was released by: Streetinsider.com and their article: “Penumbra, Inc. (PEN) Tops Q1 EPS by 17c, Beats on Revenues; Boosts FY18 Revenue Outlook Above Consensus” with publication date: May 08, 2018.

Penumbra, Inc. (NYSE:PEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: